Jeffrey Hubbell to Vaccines
This is a "connection" page, showing publications Jeffrey Hubbell has written about Vaccines.
Connection Strength
2.548
-
Glycosylation-modified antigens as a tolerance-inducing vaccine platform prevent anaphylaxis in a pre-clinical model of food allergy. Cell Rep Med. 2024 01 16; 5(1):101346.
Score: 0.845
-
An optimized antigen-protein fusion. Nat Biomed Eng. 2020 06; 4(6):583-584.
Score: 0.660
-
Therapeutic synthetic and natural materials for immunoengineering. Chem Soc Rev. 2024 Feb 19; 53(4):1789-1822.
Score: 0.214
-
Vaccine nanocarriers: Coupling intracellular pathways and cellular biodistribution to control CD4 vs CD8 T cell responses. Biomaterials. 2017 07; 132:48-58.
Score: 0.133
-
A high-throughput nanoimmunoassay chip applied to large-scale vaccine adjuvant screening. Integr Biol (Camb). 2013 Apr; 5(4):650-8.
Score: 0.100
-
Nanoparticle size influences the magnitude and quality of mucosal immune responses after intranasal immunization. Vaccine. 2012 Dec 14; 30(52):7541-6.
Score: 0.098
-
Chemistry. Nanomaterials for drug delivery. Science. 2012 Jul 20; 337(6092):303-5.
Score: 0.096
-
Nanoparticle conjugation of antigen enhances cytotoxic T-cell responses in pulmonary vaccination. Proc Natl Acad Sci U S A. 2011 Nov 01; 108(44):E989-97.
Score: 0.091
-
Engineering complement activation on polypropylene sulfide vaccine nanoparticles. Biomaterials. 2011 Mar; 32(8):2194-203.
Score: 0.086
-
Lymphatic drainage function and its immunological implications: from dendritic cell homing to vaccine design. Semin Immunol. 2008 Apr; 20(2):147-56.
Score: 0.070
-
Exploiting lymphatic transport and complement activation in nanoparticle vaccines. Nat Biotechnol. 2007 Oct; 25(10):1159-64.
Score: 0.068
-
Targeting dendritic cells with biomaterials: developing the next generation of vaccines. Trends Immunol. 2006 Dec; 27(12):573-9.
Score: 0.064
-
Engineering approaches to immunotherapy. Sci Transl Med. 2012 Aug 22; 4(148):148rv9.
Score: 0.024